|
|
|
|
|
|
|
|
|
|
Abstract
As we previously showed, we have
synthesized a new family of 17β-estradiol-platinum(II) hybrids. Earlier
studies revealed
the VP-128 hybrid to show high efficiency compared
with cisplatin toward hormone-dependent breast cancer cells. In the
present
research, we have studied the antitumor activity of
VP-128 in vitro and in vivo against ovarian cancer. In nude mice with
ovarian xenografts, VP-128 displayed selective
activity toward hormone-dependent tumors and showed higher efficiency
than
cisplatin to inhibit tumor growth..............
Altogether these results highlight the beneficial value of VP-128 for
the treatment
of hormone-dependent ovarian cancers and provide
preliminary proof of concept for the efficient targeting of ERα- by
17β-estradiol-Pt(II)-linked
chemotherapeutic hybrids in these tumors.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.